| __timestamp | Exelixis, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23068000 | 2614539000 |
| Thursday, January 1, 2015 | 33277000 | 3711019000 |
| Friday, January 1, 2016 | 184902000 | 4560733000 |
| Sunday, January 1, 2017 | 437411000 | 5475166000 |
| Monday, January 1, 2018 | 827478000 | 6276700000 |
| Tuesday, January 1, 2019 | 934678000 | 7081200000 |
| Wednesday, January 1, 2020 | 951266000 | 7377200000 |
| Friday, January 1, 2021 | 1382097000 | 13634200000 |
| Saturday, January 1, 2022 | 1553153000 | 10612500000 |
| Sunday, January 1, 2023 | 1757661000 | 11301400000 |
| Monday, January 1, 2024 | 2168701000 | 12231500000 |
Unlocking the unknown
In the competitive world of biotechnology, Regeneron Pharmaceuticals, Inc. and Exelixis, Inc. have carved out significant niches. Over the past decade, Regeneron has consistently outperformed Exelixis in terms of gross profit, showcasing a robust growth trajectory. From 2014 to 2023, Regeneron's gross profit surged by approximately 330%, peaking at over $11 billion in 2023. In contrast, Exelixis, while showing impressive growth, increased its gross profit by nearly 7,500%, reaching $1.76 billion in the same year.
This stark difference highlights Regeneron's dominant market position, driven by its innovative drug pipeline and strategic partnerships. Meanwhile, Exelixis's rapid growth, especially post-2016, underscores its successful product launches and expanding market presence. As the biotech landscape evolves, these two companies exemplify the dynamic nature of the industry, each charting its own path to success.
Novo Nordisk A/S and Exelixis, Inc.: A Detailed Gross Profit Analysis
Merck & Co., Inc. and Exelixis, Inc.: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Key Insights on Gross Profit: Regeneron Pharmaceuticals, Inc. vs Incyte Corporation
Regeneron Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc: A Detailed Gross Profit Analysis
Regeneron Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Who Generates Higher Gross Profit? Regeneron Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.
Key Insights on Gross Profit: Regeneron Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Gross Profit Analysis: Comparing Exelixis, Inc. and Halozyme Therapeutics, Inc.
Gross Profit Analysis: Comparing Exelixis, Inc. and Jazz Pharmaceuticals plc
Who Generates Higher Gross Profit? Exelixis, Inc. or Supernus Pharmaceuticals, Inc.